310 related articles for article (PubMed ID: 30076961)
1. Altered structure and function of fibrinogen after cleavage by Factor VII Activating Protease (FSAP).
Etscheid M; Subramaniam S; Lochnit G; Zabczyk M; Undas A; Lang IM; Hanschmann KM; Kanse SM
Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3397-3406. PubMed ID: 30076961
[TBL] [Abstract][Full Text] [Related]
2. Decreased plasmin resistance by clots of a homophenotypic Aalpha R 16H fibrinogen (Kingsport, slower fibrinopeptide A than fibrinopeptide B release).
Galanakis DK; Neerman-Arbez M; Kudryk B; Henschen A
Blood Coagul Fibrinolysis; 2010 Mar; 21(2):135-9. PubMed ID: 20019599
[TBL] [Abstract][Full Text] [Related]
3. Reduced plasminogen binding and delayed activation render γ'-fibrin more resistant to lysis than γA-fibrin.
Kim PY; Vu TT; Leslie BA; Stafford AR; Fredenburgh JC; Weitz JI
J Biol Chem; 2014 Oct; 289(40):27494-503. PubMed ID: 25128532
[TBL] [Abstract][Full Text] [Related]
4. The alphaC domains of fibrinogen affect the structure of the fibrin clot, its physical properties, and its susceptibility to fibrinolysis.
Collet JP; Moen JL; Veklich YI; Gorkun OV; Lord ST; Montalescot G; Weisel JW
Blood; 2005 Dec; 106(12):3824-30. PubMed ID: 16091450
[TBL] [Abstract][Full Text] [Related]
5. Streptococcus gordonii FSS2 Challisin affects fibrin clot formation by digestion of the αC region and cleavage of the N -terminal region of the Bβ chains of fibrinogen.
Harty DW; Farahani RM; Simonian MR; Hunter L; Hunter N
Thromb Haemost; 2012 Aug; 108(2):236-46. PubMed ID: 22552295
[TBL] [Abstract][Full Text] [Related]
6. Factor VII activating protease (FSAP) inhibits the outcome of ischemic stroke in mouse models.
Kim JY; Manna D; Etscheid M; Leergaard TB; Kanse SM
FASEB J; 2022 Oct; 36(10):e22564. PubMed ID: 36165219
[TBL] [Abstract][Full Text] [Related]
7. The frequent Marburg I polymorphism impairs the pro-urokinase activating potency of the factor VII activating protease (FSAP).
Roemisch J; Feussner A; Nerlich C; Stoehr HA; Weimer T
Blood Coagul Fibrinolysis; 2002 Jul; 13(5):433-41. PubMed ID: 12138371
[TBL] [Abstract][Full Text] [Related]
8. Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis.
Kwasny-Krochin B; Gluszko P; Undas A
Thromb Res; 2010 Jul; 126(1):e11-6. PubMed ID: 20471669
[TBL] [Abstract][Full Text] [Related]
9. Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen.
Hugenholtz GC; Macrae F; Adelmeijer J; Dulfer S; Porte RJ; Lisman T; Ariëns RA
J Thromb Haemost; 2016 May; 14(5):1054-66. PubMed ID: 26833718
[TBL] [Abstract][Full Text] [Related]
10. MASP-1 of the complement system alters fibrinolytic behaviour of blood clots.
Jenny L; Noser D; Larsen JB; Dobó J; Gál P; Pál G; Schroeder V
Mol Immunol; 2019 Oct; 114():1-9. PubMed ID: 31325724
[TBL] [Abstract][Full Text] [Related]
11. A novel natural mutation AαPhe98Ile in the fibrinogen coiled-coil affects fibrinogen function.
Riedelová-Reicheltová Z; Kotlín R; Suttnar J; Geierová V; Riedel T; Májek P; Dyr JE
Thromb Haemost; 2014 Jan; 111(1):79-87. PubMed ID: 24108601
[TBL] [Abstract][Full Text] [Related]
12. The sequence of cleavage of fibrinopeptides from fibrinogen is important for protofibril formation and enhancement of lateral aggregation in fibrin clots.
Weisel JW; Veklich Y; Gorkun O
J Mol Biol; 1993 Jul; 232(1):285-97. PubMed ID: 8331664
[TBL] [Abstract][Full Text] [Related]
13. Partial deletion of the αC-domain in the Fibrinogen Perth variant is associated with thrombosis, increased clot strength and delayed fibrinolysis.
Westbury SK; Duval C; Philippou H; Brown R; Lee KR; Murden SL; Phillips E; Reilly-Stitt C; Whalley D; Ariëns RA; Mumford AD
Thromb Haemost; 2013 Dec; 110(6):1135-44. PubMed ID: 24048413
[TBL] [Abstract][Full Text] [Related]
14. Incorporation of fibrin molecules containing fibrinopeptide A alters clot ultrastructure and decreases permeability.
Flood VH; Nagaswami C; Chernysh IN; Al-Mondhiry HA; Weisel JW; Farrell DH
Br J Haematol; 2007 Jul; 138(1):117-24. PubMed ID: 17555455
[TBL] [Abstract][Full Text] [Related]
15. Unfavorably Altered Fibrin Clot Properties in Patients with Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Association with Thrombin Generation and Eosinophilia.
Mastalerz L; Celińska-Lӧwenhoff M; Krawiec P; Batko B; Tłustochowicz W; Undas A
PLoS One; 2015; 10(11):e0142167. PubMed ID: 26540111
[TBL] [Abstract][Full Text] [Related]
16. In vitro fibrin clot formation and fibrinolysis using heterozygous plasma fibrinogen from gammaAsn319, Asp320 deletion dysfibrinogen, Otsu I.
Terasawa F; Kani S; Hongo M; Okumura N
Thromb Res; 2006; 118(5):651-61. PubMed ID: 16412498
[TBL] [Abstract][Full Text] [Related]
17. Increased plasma clot permeability and susceptibility to lysis are associated with heavy menstrual bleeding of unknown cause: a case-control study.
Szczepaniak P; Zabczyk M; Undas A
PLoS One; 2015; 10(4):e0125069. PubMed ID: 25909989
[TBL] [Abstract][Full Text] [Related]
18. Extracellular histones promote fibrinolysis by single-chain urokinase-type plasminogen activator in a factor seven activating protease-dependent way.
Semeraro F; Ammollo CT; Semeraro N; Colucci M
Thromb Res; 2020 Dec; 196():193-199. PubMed ID: 32891905
[TBL] [Abstract][Full Text] [Related]
19. Factor VII and single-chain plasminogen activator-activating protease: activation and autoactivation of the proenzyme.
Kannemeier C; Feussner A; Stöhr HA; Weisse J; Preissner KT; Römisch J
Eur J Biochem; 2001 Jul; 268(13):3789-96. PubMed ID: 11432747
[TBL] [Abstract][Full Text] [Related]
20. A Positively Charged Surface Triggers Coagulation Activation Through Factor VII Activating Protease (FSAP).
Sperling C; Maitz MF; Grasso S; Werner C; Kanse SM
ACS Appl Mater Interfaces; 2017 Nov; 9(46):40107-40116. PubMed ID: 29091393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
